Quarterly Report Q3 2017

April 16, 2018

Prometic 2017 Third Quarter Financial Results and Highlights:

  •  US $80 million (CAD $100 million) line of credit secured from Structured Alpha LP
  •  Plasminogen BLA accepted by FDA, PDUFA date fixed at April 14, 2018
  •  Plasminogen granted rare pediatric disease designation by FDA and priority review status by Health Canada
  •  PBI-4050 granted Fast Track designation for IPF and green light to initiate the pivotal phase 2/3 clinical trials
  •  Conference call and live webcast at 11:00 am ET on Tuesday November 14
Previous Flipbook
Management Information Circular 2017
Management Information Circular 2017

Notice is hereby given that the Annual and Special Meeting of Shareholders (the "Meeting") of Prometic Life...

Next Flipbook
Quarterly Report Q2 2017
Quarterly Report Q2 2017

Prometic reports 2017 second quarter highlights and financial results